Superiority of levosimendan over dobutamine in right ventricle failure.
Yontar
Osman Can
OC
Yalta
Kenan
K
Yilmaz
Mehmet Birhan
MB
D002316:Cardiotonic Agents / Q000008:administration & dosage*; D003422:Critical Care / Q000379:methods; D016638:Critical Illness; D004280:Dobutamine / Q000008:administration & dosage*; D005260:Female; D006334:Heart Function Tests; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage*; D006976:Hypertension, Pulmonary / Q000517:prevention & control; D007362:Intensive Care Units; D008297:Male; D009203:Myocardial Infarction / Q000150:complications; D011379:Prognosis; D011724:Pyridazines / Q000008:administration & dosage*; D012770:Shock, Cardiogenic / Q000150:complications; D000077464:Simendan; D015996:Survival Rate; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects; D018497:Ventricular Dysfunction, Right / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan; D004280:Dobutamine